TRCT
RKDA icon

Tower Research Capital (TRC)’s Arcadia Biosciences RKDA Stock Holding History

Tower Research Capital (TRC)’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,940
Closed -$5.44K – 5565
2026
Q1 		$5.44K Buy
3,940
+2,464
+167% +$4.83K ﹤0.01% 4122
2025
Q4 		$2.92K Sell
1,476
-211
-13% -$777 ﹤0.01% 4452
2025
Q3 		$5.85K Sell
1,687
-228
-12% -$932 ﹤0.01% 4196
2025
Q2 		$8.25K Buy
1,915
+1,478
+338% +$5.84K ﹤0.01% 4022
2025
Q1 		$1.3K Buy
+437
New +$1.89K ﹤0.01% 4741
2024
Q4 		– Sell
-1,764
Closed -$4.82K – 5950
2024
Q3 		$4.82K Sell
1,764
-19
-1% -$55 ﹤0.01% 4411
2024
Q2 		$5.62K Sell
1,783
-1,991
-53% -$5.04K ﹤0.01% 4668
2024
Q1 		$8.34K Buy
3,774
+894
+31% +$2.32K ﹤0.01% 4033
2023
Q4 		$9.01K Buy
2,880
+568
+25% +$1.78K ﹤0.01% 4446
2023
Q3 		$7.75K Sell
2,312
-620
-21% -$2.54K ﹤0.01% 4438
2023
Q2 		$11.4K Buy
2,932
+2,930
+146,500% +$15.6K ﹤0.01% 3982
2023
Q1 		$0 Sell
2
-267
-99% -$2.83K ﹤0.01% 6201
2022
Q4 		$3K Sell
269
-13
-5% -$185 ﹤0.01% 5223
2022
Q3 		$6K Sell
282
-20
-7% -$682 ﹤0.01% 5040
2022
Q2 		$12K Buy
302
+296
+4,933% +$13.6K ﹤0.01% 4304
2022
Q1 		$0 Buy
+6
New +$286 ﹤0.01% 6474
2021
Q4 		– Sell
-6
Closed – – 6503
2021
Q3 		$0 Sell
6
-38
-86% -$3.56K ﹤0.01% 6104
2021
Q2 		$5K Sell
44
-150
-77% -$16.4K ﹤0.01% 4733
2021
Q1 		$21K Buy
194
+167
+619% +$20.5K ﹤0.01% 3847
2020
Q4 		$3K Sell
27
-65
-71% -$7.93K ﹤0.01% 4823
2020
Q3 		$10K Buy
+92
New +$12.4K ﹤0.01% 4103
2020
Q2 		– Sell
-2
Closed – – 4951
2020
Q1 		$0 Buy
+2
New +$348 ﹤0.01% 3762
2017
Q3 		– Sell
-11
Closed -$4K – 4089
2017
Q2 		$4K Buy
11
+10
+1,000% +$5.58K ﹤0.01% 2115
2017
Q1 		$1K Sell
1
-19
-95% -$13.7K ﹤0.01% 2833
2016
Q4 		$15K Buy
20
+14
+233% +$15.9K ﹤0.01% 2381
2016
Q3 		$10K Buy
+6
New +$10.6K ﹤0.01% 2071
2016
Q2 		– Hold
0
– – – 4884
2016
Q1 		– Sell
-1
Closed -$2K – 4794
2015
Q4 		$2K Sell
1
-8
-89% -$20.8K ﹤0.01% 3798
2015
Q3 		$21K Buy
+9
New +$37.5K ﹤0.01% 1692

Other funds holding RKDA

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BWM
Bullock Wealth Management Bloomington, Indiana $231M AUM

Tower Research Capital (TRC)'s RKDA Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Arcadia Biosciences (RKDA) in Q2 2026, closing a stake of 3,940 shares — an estimated $5.44K sold.

Tower Research Capital (TRC) first reported a position in RKDA in Q3 2015 and held it in 28 quarters. The position peaked at $21K in Q1 2021. 18 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Arcadia Biosciences position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,940 Arcadia Biosciences shares in Q2 2026, an estimated $5.44K.
  • Tower Research Capital (TRC) first reported a position in Arcadia Biosciences in Q3 2015 and held it in 28 quarters.
  • Tower Research Capital (TRC)'s Arcadia Biosciences position peaked at $21K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.